AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00325715

Enrollment

150

Registered

2006-05-15

Start date

2006-04-30

Completion date

2006-08-31

Last updated

2011-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic Ulcer

Brief summary

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

Interventions

DRUGAGN 201904

DRUGesomeprazole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy Adult Volunteers who have provided written informed consent

Exclusion criteria

* Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease. * Female volunteers who pregnant, nursing, or planning a pregnancy * Volunteers with a history of drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
Stomach or upper intestinal erosions	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026